Aimeike signs distribution cooperation framework agreement with South Korea huons BP
AMEC announced that it had signed a distribution cooperation framework agreement with South Korea's huons BP, agreeing that the company would introduce huonsbp's botulinum toxin products by means of R & D and registration.
This text is a result of machine translation.
Related companies：
In-depth
Technology, Healthcare
Pure Global: The International Engine of Medical Technology Globalization
As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.
Sep 28, 2023 09:30 AM
Briefing Feb 25, 2022 09:58 AM
· Healthcare
The steel sector strengthened significantly
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Dec 09, 2021 10:39 AM
Baijiu plate strength, mouth cellar line exceeds 10%
Briefing Oct 22, 2021 10:13 PM
· Real Estate
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
Briefing Oct 19, 2021 06:56 AM
· Financials
The investment banking business was strictly supervised, and seven securities companies received fines
Briefing Oct 17, 2021 06:26 PM
· Healthcare
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
Briefing Sep 24, 2021 11:28 AM
· Healthcare
The medical and American plate rose sharply
Briefing Aug 23, 2021 07:46 PM
· Healthcare
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
Briefing Jul 08, 2021 07:41 PM
· Financials
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth